An Oncolytic Viral Strategy for Treating Cancer
Figure 1. Microscopic images of Cells 48 hours after inoculation without virus (Control – left) and with recombinant virus at a multiplicity of infection (MYXV Red – center, and MYXV OfrC – right). Tomato red protein expression by both recombinat viruses is observed in various cancer cell cultures.
Available for Licensing or
Provisional Patent Filed
At A Glance
- Genetic Modification of an oncolytic virus greatly enhances lysis of cancerous cells
- Enhanced lysis substantially improves cancer treatment and has been shown to work on rabbit and canine cell types
- The virus can lyse a variety of cancerous cell types and could be used to cure a broad spectrum of cancers in both pets and humans
Current cancer treatments are generally non-specific and have many adverse side effects. Additionally, they aren’t always efficacious, with some cancers still very unlikely to treat. Oncolytic virus treatments offer a novel targeted approach to defeating cancer. These treatments are somewhat new to the field, with current companies in Phase I-III clinical trials. Although relatively new, large pharmaceutical companies have been acquiring these startups, indicating these technologies are desirable. With genetic modifications, these viruses can be enhanced to improve the likelihood of lysing cancerous cells. These modifications could greatly reduce time to treatment while also providing the ability to cure many types of cancer.
A group of researchers at Colorado State University have genetically altered an oncolytic virus to greatly enhance its ability to kill cancer cells. Using this modified virus, this group has shown improved lysis of different types of cancerous cells from different mammalian cell lines. Their findings build the groundwork to apply this treatment in a veterinary setting with the potential to move into human applications.
- Genetic modification has shown improved lysis of cancerous cells
- Can apply treatment to many different cancer types
- Specifically targets cancerous cells while leaving non-cancerous cells intact
Figure 2. Detection of Annexin V-labeled cells using a RealTime-Glo Annexin V Apoptosis and Necrosis Assay. Apoptosis (indicated by luminescence units) was significantly higher in MYXV ORfC-infected cells as compared to MYXV Red-infected cells.
Last updated: December 2019